All In Biotech

Drug Trial Radar · NCT07923760

Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.

Opioid Physiology and Individual Outcomes With Supplemental O₂ (OPIO2)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 1, 2031

Study completion Dec 1, 2031

Sponsor

Lead sponsor
University of California, San DiegoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate whether supplemental oxygen given during sleep improves breathing stability and sleep-disordered breathing in adults who use prescription opioids long term. Participants will receive both supplemental oxygen and sham air during separate overnight sleep studies in a randomized order. The two study conditions will be separated by a washout period of approximately one week. Researchers will compare breathing during sleep with supplemental oxygen versus sham air and will also evaluate measures of oxygen levels, carbon dioxide levels, sleep quality, alertness, and other aspects of breathing and sleep. For participants who previously took part in the GENESIS study, qualifying assessments from that study may be used to meet certain baseline requirements when appropriate, which may reduce the need to repeat some testing.

Conditions

  • Sleep-disordered Breathing
  • Chronic Opioid Use

Interventions

  • Sham AirOther

    Sham air will be delivered during sleep through a nasal cannula using a standard wall air flow controller during an in-laboratory overnight polysomnography (PSG). Sham air will be delivered at a fixed flow rate of 4 L/min and may be reduced to 3 L/min for participant comfort.

  • Supplemental OxygenDrug

    Supplemental oxygen will be delivered during sleep through a nasal cannula using a standard wall oxygen flow controller during an in-laboratory overnight polysomnography (PSG). Supplemental oxygen will be delivered at a fixed flow rate of 4 L/min and may be reduced to 3 L/min for participant comfort.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Flow-Based Apnea-Hypopnea Index (AHIflow)Time frame: During each overnight intervention PSG, approximately 1 week apart

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altman Clinical and Translational Research Institute

    La Jolla, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.